Cargando…

Immune-Related Meningoencephalitis following Nivolumab in Metastatic Renal Cell Carcinoma

While immunotherapy with nivolumab is promising for patients with renal cell carcinoma (RCC), overactivation of the immune system can lead to serious side effects. Immune-related meningoencephalitis without a viral or microbial etiology is a rare complication that may occur in patients treated with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shields, Lisa B.E., Alsorogi, Mohammad S., Mar, Nataliya, Rezazadeh Kalebasty, Arash
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299396/ https://www.ncbi.nlm.nih.gov/pubmed/34326741 http://dx.doi.org/10.1159/000513001

Ejemplares similares

Metastatic clear cell renal cell carcinoma in isolated retroperitoneal lymph node without evidence of primary tumor in kidneys: A case report
por: Shields, Lisa BE, et al.
Publicado: (2020)

Concurrent renal cell carcinoma and hematologic malignancies: Nine case reports
por: Shields, Lisa BE, et al.
Publicado: (2020)

Thromboembolic events in metastatic testicular cancer treated with cisplatin-based chemotherapy
por: Shields, Lisa B E, et al.
Publicado: (2021)

Spontaneous Regression of Delayed Pulmonary and Mediastinal Metastases from Clear Cell Renal Cell Carcinoma
por: Shields, Lisa B.E., et al.
Publicado: (2020)

Immunotherapy With Checkpoint Inhibitors in FGFR-Altered Urothelial Carcinoma
por: Benjamin, David J, et al.
Publicado: (2022)

Nivolumab: Immune-related meningoencephalitis: case report
Publicado: (2021)

Late recurrence of localized pure seminoma in prostate gland: A case report
por: Baweja, Abinav, et al.
Publicado: (2022)

Personalized chemotherapy in clear cell adenocarcinoma of the urethra: A case report
por: Shields, Lisa B E, et al.
Publicado: (2020)

Drug extravasation with Enfortumab vedotin
por: Grant, Christopher Ryan, et al.
Publicado: (2023)

Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial
por: George, Daniel J, et al.
Publicado: (2022)

Herpes Simplex Virus Type 2 Radiculomyelitis Disguised as Conversion Disorder
por: Shields, Lisa B.E., et al.
Publicado: (2019)

Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920
por: Emamekhoo, Hamid, et al.
Publicado: (2021)

Treatment approaches for urachal cancer: Use of immunotherapy and targeted therapies
por: Benjamin, David J, et al.
Publicado: (2023)

Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial
por: Tykodi, Scott S, et al.
Publicado: (2022)

Severe immune thrombocytopenia induced by nivolumab in a patient with metastatic renal cell carcinoma
por: Hata, Shinro, et al.
Publicado: (2020)

REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study
por: Vauchier, Charles, et al.
Publicado: (2022)

Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report
por: Miyauchi, Yasuyuki, et al.
Publicado: (2021)

Prostate Cancer in Sexual Minorities: Epidemiology, Screening and Diagnosis, Treatment, and Quality of Life
por: Yazdanpanah, Omid, et al.
Publicado: (2023)

Re-Challenging with Nivolumab in Metastatic Renal Cell Carcinoma After Immune-Related Interstitial Pneumonia: A Case Report
por: Shibata, Yosuke, et al.
Publicado: (2021)

Cabozantinib‐nivolumab sequence in metastatic renal cell carcinoma: The CABIR study
por: Vano, Yann‐Alexandre, et al.
Publicado: (2022)

Severe Immune-Related Adverse Events in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with PDCD1 Polymorphism
por: Kobayashi, Mizuki, et al.
Publicado: (2022)

Role of the Systemic Immune-Inflammation Index in Patients with Metastatic Renal Cell Carcinoma Treated with First-Line Ipilimumab plus Nivolumab
por: Stühler, Viktoria, et al.
Publicado: (2022)

Nivolumab versus Cabozantinib: Comparing Overall Survival in Metastatic Renal Cell Carcinoma
por: Wiecek, Witold, et al.
Publicado: (2016)

Possible abscopal effect after discontinuation of nivolumab in metastatic renal cell carcinoma
por: Nakajima, Nobuyuki, et al.
Publicado: (2020)

Sicca syndrome during ipilimumab and nivolumab therapy for metastatic renal cell carcinoma
por: Segawa, Takuya, et al.
Publicado: (2023)

Nivolumab–ipilimumab in renal cell carcinoma metastatic to the bones: A case report
por: Di Napoli, Marilena, et al.
Publicado: (2022)

Significance of timing of therapeutic line on effectiveness of nivolumab for metastatic renal cell carcinoma
por: Teishima, Jun, et al.
Publicado: (2023)

Sodium Levels and Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving Nivolumab
por: Catalano, Martina, et al.
Publicado: (2023)

A case of multiple metastatic sarcomatoid renal cell carcinoma with complete response to nivolumab
por: Tomioka, Masayuki, et al.
Publicado: (2021)

Ipilimumab and Nivolumab induced ventricular tachycardia in a patient with metastatic renal cell carcinoma
por: Savarapu, Pramod, et al.
Publicado: (2021)

Association of Energy Expenditure and Efficacy in Metastatic Renal Cell Carcinoma Patients Treated with Nivolumab
por: Noel, Johanna, et al.
Publicado: (2022)

Everolimus and/or Nivolumab-Associated Cytomegalovirus Colitis in a Patient with Metastatic Renal Cell Carcinoma
por: Ismayilov, Rashad, et al.
Publicado: (2022)

Primary resistance to nivolumab plus ipilimumab therapy in patients with metastatic renal cell carcinoma
por: Numakura, Kazuyuki, et al.
Publicado: (2023)

Calcitriol-mediated hypercalcemia as an immune-related adverse event in a patient receiving nivolumab and ipilimumab for metastatic renal cell carcinoma, case report
por: Johnson, Kai, et al.
Publicado: (2021)

Metastatic Merkel cell carcinoma response to nivolumab
por: Walocko, Frances M., et al.
Publicado: (2016)

Nivolumab for Metastatic Cutaneous Squamous Cell Carcinoma
por: Oro-Ayude, Marcos, et al.
Publicado: (2020)

Pathological complete response after nivolumab therapy following angiogenesis inhibitors in a patient with metastatic renal cell carcinoma
por: Hagimoto, Hiroki, et al.
Publicado: (2020)

Markers of inflammation are associated with clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab
por: Sznol, Mario, et al.
Publicado: (2015)

Pathologic Complete Response to Neoadjuvant Nivolumab/Ipilimumab in a Patient with Metastatic Renal Cell Carcinoma
por: Peak, Taylor C., et al.
Publicado: (2020)

Complete response to nivolumab for metastatic renal cell carcinoma on hemodialysis patient; a case report
por: Ito, Akito, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_0drp41odkta3iipmtl9sq4erec